| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of ...
- Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and...
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of ...
JMP Securities analyst Silvan Tuerkcan reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Market Outperform and maintains ...
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of ...
JMP Securities analyst Silvan Tuerkcan reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Market Outperform and maintains ...